Disinfection of bronchoscopes, contaminated in vitro with Mycobacterium tuberculosis, Mycobacterium avium-intracellulare and Mycobacterium chelonae in sputum, using stabilized, buffered peracetic acid solution ('Nu-Cidex')

1997 ◽  
Vol 37 (2) ◽  
pp. 137-143 ◽  
Author(s):  
A Middleton
2010 ◽  
Vol 54 (6) ◽  
pp. 2534-2539 ◽  
Author(s):  
Devyani Deshpande ◽  
Shashikant Srivastava ◽  
Claudia Meek ◽  
Richard Leff ◽  
Gerri S. Hall ◽  
...  

ABSTRACT Organisms of the Mycobacterium avium-intracellulare complex (MAC) have been demonstrated to be susceptible to moxifloxacin. However, clinical data on how to utilize moxifloxacin to treat disseminated MAC are scanty. In addition, there have been no moxifloxacin pharmacokinetic-pharmacodynamic (PK/PD) studies performed for MAC infection. We utilized an in vitro PK/PD model of intracellular MAC to study moxifloxacin PK/PD for disseminated disease. Moxifloxacin doses, based on a serum half-life of 12 h, were administered, and the 0- to 24-h area under the concentration-time curve (AUC0-24) to MIC ratios associated with 1.0 log10 CFU/ml per week kill and 90% of maximal kill (EC90) were identified. The AUC0-24/MIC ratio associated with 1.0 log10 CFU/ml kill was 17.12, and that with EC90 was 391.56 (r 2 = 0.97). Next, the moxifloxacin MIC distribution in 102 clinical isolates of MAC was identified. The median MIC was 1 to 2 mg/liter. Monte Carlo simulations of 10,000 patients with disseminated MAC were performed to determine the probability that daily moxifloxacin doses of 400 and 800 mg/day would achieve or exceed 1.0 log10 CFU/ml per week kill or EC90. Doses of 400 and 800 mg/day achieved the AUC0-24/MIC ratio of 17.12 in 64% and 92% of patients, respectively. The critical concentration of moxifloxacin against MAC was identified as 0.25 mg/liter in Middlebrook media. The proposed susceptibility breakpoint means that a larger proportion of clinical isolates is resistant to moxifloxacin prior to therapy. For patients infected with susceptible isolates, however, 800 mg a day should be examined for safety and efficacy for disseminated M. avium disease.


2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
Christine Goepfert ◽  
Nadine Regenscheit ◽  
Vanessa Schumacher ◽  
Simone Roos ◽  
Christophe Rossier ◽  
...  

Mycobacterium aviumsubsp.avium(Maa) is an intracellular pathogen belonging to theMycobacterium avium-intracellularecomplex (MAC). Reservoirs of MAC are the natural environment, wildlife and domestic animals. In adult bovine, MAC infections are typically caused byMycobacterium aviumsubsp.paratuberculosis(Map). Maa infections in bovine are rarely reported but may cause clinical disease and pathological lesions similar to those observed in paratuberculosis or those induced by members of theMycobacterium tuberculosiscomplex (MTBC). Therefore, differentiation of MAC from MTBC infection should be attempted, especially if unusual mycobacterial lesions are encountered. Four veal calves from a fattening farm dying with clinical signs of otitis media, fever, and weight loss were submitted for necropsy. Samples from affected organs were taken for histologic investigation, bacteriologic culture, and bacterial specification using PCR. Macroscopic thickening of the intestinal mucosa was induced by granulomatous enteritis and colitis. Intracytoplasmic acid-fast bacteria were detected by Ziehl-Neelsen stains and PCR revealed positive results forMycobacterium aviumsubsp.avium. Clinical and pathological changes of Maa infection in veal calves had features ofMycobacterium aviumsubsp.paratuberculosisand the MTBC. Therefore,Mycobacterium tuberculosiscomplex infection should be considered in cases of granulomatous enteritis in calves.


Author(s):  
Elena Portell-Buj ◽  
Alexandre López-Gavín ◽  
Julian González-Martín ◽  
Griselda Tudó

2013 ◽  
Vol 634-638 ◽  
pp. 1371-1375
Author(s):  
Zhi Jun Xin ◽  
Zhong Jia ◽  
Dian He ◽  
Jian Ping Liang ◽  
Lei Tao ◽  
...  

A series of N-(pyridin-4-yl) salicylamides derivatives were prepared through acylation of the corresponding acetylsalicyloyl chlorides with substituted 4-amino-pyridines. These compounds were evaluated in vitro for antimycobacterial activities against Mycobacterium tuberculosis (TB) and Mycobacterium avium (A) by the minimum inhibitory concentrations (MIC) values. Eight of the compounds exhibited lower MIC against A than isoniazide (INH). Meanwhile, four of the compounds exhibited good anti-TB activity, when they were compared with INH. Antimycobacterial activities of N-(pyridin-4-yl) salicylamides were influenced by the balance between hydrophobicity and electron-withdrawing substituent effect on the phenyl and pyridine ring. These studies show that these compounds might serve as prospective wide-spectrum antimycobacterial substances.


1992 ◽  
Vol 78 (1-3) ◽  
pp. 227-235 ◽  
Author(s):  
Burkhard V. Wichert ◽  
Ricardo J. Gonzalez-Rothi ◽  
Leslie E. Straub ◽  
Birgit M. Wichert ◽  
Hans Schreier

Sign in / Sign up

Export Citation Format

Share Document